Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?

Nature Clinical Practice Nephrology volume 2, pages 612–613 (2006)Cite this article

boxed-textThornley-Brown D et al. (2006) Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med 166: 797–805

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jandeleit-Dahm KA et al. (2005) Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463–473

    Article  CAS  Google Scholar 

  2. Elliott WJ (2005) Differential effects of antihypertensive drugs on new-onset diabetes? Curr Hypertens Rep 7: 249–256

    Article  CAS  Google Scholar 

  3. Gress TW et al. (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342: 905–912

    Article  CAS  Google Scholar 

  4. Tikellis C et al. (2004) Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53: 989–997

    Article  CAS  Google Scholar 

  5. Ko SH et al. (2004) Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 316: 114–122

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Senior Research Fellow and Head of the Diabetes and Kidney Laboratory at the Baker Heart Research Institute, Melbourne, Australia

    Karin Jandeleit-Dahm

Authors
  1. Karin Jandeleit-Dahm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Jandeleit-Dahm.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jandeleit-Dahm, K. Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?. Nat Rev Nephrol 2, 612–613 (2006). https://doi.org/10.1038/ncpneph0312

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0312

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing